GlassScriptPhysician profile
Matthew C Steele
NPI 1508180324
$5,136.10
in general payments reported to CMS, 2019-2025
49 companies · $566 in 2025
The $566 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $587 · 2021: $881 · 2022: $694 · 2023: $552 · 2024: $921 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035 · Education: $3.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.62 |
| Education | $3.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $690.89 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $466.24 | 2019-2025 | |
| Janssen Biotech, INC. | $386.17 | 2020-2025 | Erleada |
| Abbvie INC. | $303.62 | 2019-2025 | Botox |
| Dendreon Pharmaceuticals LLC | $261.67 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $249.38 | 2021-2025 | Prolaris, Myrisk |
| Teleflex LLC | $221.39 | 2021-2025 | Barrigel |
| Endo Pharmaceuticals INC. | $199.41 | 2019-2021 | |
| Boston Scientific Corporation | $189.17 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue |
| Blue Earth Diagnostics | $173.28 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $167.42 | 2023-2024 | Orgovyx, Gemtesa |
| Amgen INC. | $152.62 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $151.00 | 2020-2025 | Adstiladrin |
| Pfizer INC. | $149.00 | 2019-2025 | |
| C. R. Bard, INC. & Subsidiaries | $124.28 | 2019-2024 | Bard Urinary Drainage Bag |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $115.46 | 2020-2023 | Jelmyto |
| Rochester Medical Corporation | $93.71 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $71.09 | 2019-2022 | |
| Allergan, INC. | $68.57 | 2019-2020 | |
| Travere Therapeutics, INC. | $65.71 | 2019-2023 | Thiola |
| Myovant Sciences INC. | $59.58 | 2022 | |
| Medtronic, INC. | $56.26 | 2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $55.75 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $44.60 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $43.82 | 2024-2025 | Trelstar |
| Calyxo, INC. | $39.53 | 2024-2025 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $37.64 | 2020-2023 | Aquabeam Robotic System |
| Civco Medical Instruments | $37.36 | 2024-2025 | |
| Agiliti Surgical, INC. | $36.21 | 2024-2025 | Sonablate Hifu, Soltive Superpulsed Laser, Koelis Trinity Fusion Biopsy System |
| Coloplast Corp | $36.04 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $34.40 | 2021-2023 | Oxlumo |
| Angiodynamics, INC. | $33.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $32.52 | 2021-2023 | Lynparza |
| Ambu INC. | $27.90 | 2020-2021 | |
| Neotract INC. | $24.15 | 2019 | |
| Abbott Laboratories | $23.61 | 2020-2021 | |
| Axonics, INC. | $22.95 | 2024 | Bulkamid |
| Tolmar, INC. | $21.33 | 2023 | |
| Merck Sharp & Dohme LLC | $20.21 | 2022 | |
| Antares Pharma, INC. | $19.74 | 2020 | |
| Therapeuticsmd, INC. | $16.12 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $15.32 | 2019 | |
| Baudax Bio INC. | $15.26 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.88 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.86 | 2022 | |
| Olympus America INC. | $14.43 | 2023 | Itind System |
| Biocompatibles, INC. | $13.44 | 2019 | |
| Mission Pharmacal Company | $13.34 | 2019 | |
| Metuchen Pharmaceuticals | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.